Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation
The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.
You may also be interested in...
Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.
Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?
Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.
Unpicking The CMS Guide On Price Negotiation: A Dive Into The US Eylea Biosimilar Landscape
Generics Bulletin looks at the implications and takeaways for biosimilar sponsors following the recent publication of long-awaited CMS guidance on price negotiation under the Inflation Reduction Act.